Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$38,846 | -$42,684 | -$52,195 | -$191,935 |
| Dep. & Amort. | $2,566 | $3,135 | $3,441 | $5,026 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $5,004 | $6,024 | $0 |
| Change in WC | -$136 | -$876 | -$9,554 | $34 |
| Other Non-Cash | $7,839 | $963 | -$2,454 | $139,633 |
| Operating Cash Flow | -$28,577 | -$34,458 | -$54,738 | -$47,242 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$62 | -$168 | -$246 | -$44 |
| Net Acquisitions | $263 | $0 | $0 | -$31,346 |
| Inv. Purchases | -$70,987 | -$80,701 | -$84,411 | -$38,802 |
| Inv. Sales/Matur. | $74,135 | $93,516 | $154,123 | $123,697 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $3,349 | $12,647 | $69,466 | $53,505 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $50,000 | $184 | $0 | $437 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | -$1 | $1 | $0 |
| Financing Cash Flow | $50,000 | $183 | $1 | $437 |
| Forex Effect | -$1 | $0 | $0 | -$1,402 |
| Net Chg. in Cash | $24,771 | -$21,628 | $14,729 | $5,298 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $98,804 | $122,016 | $107,287 | $100,299 |
| End Cash | $123,575 | $100,388 | $122,016 | $105,597 |
| Free Cash Flow | -$28,639 | -$34,626 | -$54,984 | -$47,286 |